QT interval - PDFSEARCH.IO - Document Search Engine

QT interval
Results: 207

#	Item
91	Pfizer Inc Worldwide Regulatory Affairs and Quality Assurance 50 Pequot Avenue New London, Connecticut[removed]I . Add to Reading List Source URL: www.fda.gov Language: English - Date: 2005-01-05 16:25:56 HERG Medicinal chemistry Pharmacology Biology Syndromes QT interval Long QT syndrome Cardiac dysrhythmia Health Medicine
92	Schering-Plough Research Institute . I Add to Reading List Source URL: www.fda.gov Language: English - Date: 2005-01-05 16:25:55 Cardiac electrophysiology Circulatory system Pharmacology QT interval HERG Torsades de pointes In vivo Pre-clinical development Myocardial infarction Medicine Health Cardiac dysrhythmia
93	,,‘ /II,” A’ December 13,2004 Management Dockets, N/A Add to Reading List Source URL: www.fda.gov Language: English Medicinal chemistry Research Information Drug discovery Clinical research QT interval Comment Nonclinical studies Science Pharmacology Ion channels HERG
94	Guidance for Industry S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals Add to Reading List Source URL: www.fda.gov Language: English - Date: 2005-10-17 17:55:35 Health Cardiac electrophysiology Pharmacology Ion channels Syndromes HERG QT interval Long QT syndrome Torsades de pointes Biology Cardiac dysrhythmia Medicine
95	. AstraZenec 0 Date: December 7,2004 Add to Reading List Source URL: www.fda.gov Language: English - Date: 2005-01-05 16:25:55 Electrophysiology QT interval Electrocardiography Ion channel Biology Physiology Cardiac electrophysiology
96	LAW OFFICES HYMAN, PHELPS Add to Reading List Source URL: www.fda.gov Language: English - Date: 2004-11-23 12:17:51 QT interval Organic chemistry Norfloxacin Piperazines Chemistry Cardiac electrophysiology
97	ICH S7B Guideline Step 2 Revision The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals Add to Reading List Source URL: www.fda.gov Language: English - Date: 2004-09-10 06:20:27 Medicine Cardiac dysrhythmia HERG Long QT syndrome QT interval Torsades de pointes KvLQT1 Ventricular tachycardia Cardiac action potential Biology Cardiac electrophysiology Physiology
98	November 12,2004 i ‘1 .. I Add to Reading List Source URL: www.fda.gov Language: English - Date: 2004-11-23 12:15:18 Cardiac dysrhythmia QT interval Channelopathy Syndromes Long QT syndrome Electrocardiography Qt Torsades de pointes Software Cardiac electrophysiology Physiology
99	ABBOTT LABORATORIES Global Pharmaceutical Regulatory Affairs DouglasL. Spom Divisional Vice President Regulatory Intelligence and FDA Liaison Office Global Pharmaceutical Regulatory Affairs Add to Reading List Source URL: www.fda.gov Language: English - Date: 2005-01-05 16:25:41 Health Cardiac dysrhythmia Channelopathy Syndromes Cardiac electrophysiology QT interval Moxifloxacin Long QT syndrome Norfloxacin Chemistry Organic chemistry Piperazines
100	Guidance for Industry E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Add to Reading List Source URL: www.fda.gov Language: English - Date: 2005-10-17 17:52:11 Cardiac electrophysiology Circulatory system Piperazines QT interval Channelopathy Syndromes Long QT syndrome HERG Torsades de pointes Cardiac dysrhythmia Chemistry Physiology

UPDATE